

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/195, A61P 35/00, 17/00, 27/02	A1	(11) International Publication Number: WO 00/48590 (43) International Publication Date: 24 August 2000 (24.08.00)
(21) International Application Number: PCT/GB00/00503		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 15 February 2000 (15.02.00)		
(30) Priority Data: 9903403.5 16 February 1999 (16.02.99) GB		
(71) Applicant (<i>for all designated States except US</i>): ANGIOGENE PHARMACEUTICALS LTD. [GB/GB]; 14 Plowden Park, Aston Rowant, Watlington, Oxfordshire OX9 5SW (GB).		
(72) Inventor; and		
(75) Inventor/Applicant (<i>for US only</i>): DAVIS, Peter, David [GB/GB]; 10 Aston Park, Aston Rowant, Watlington OX9 5SW (GB).		Published <i>With international search report.</i>
(74) Agents: BAILLIE, Iain, C. et al.; Langner Parry, 52-54 High Holborn, London WC1V 6RR (GB).		

(54) Title: SUBSTITUTED STILBENE COMPOUNDS WITH VASCULAR DAMAGING ACTIVITY

(57) Abstract

Vascular damaging agents for use in treating diseases involving angiogenesis are provided which are compounds of formula: A-X-B, wherein A is a substituted cis-stilbene moiety, X a linker bond, atom or group and B is a moiety derived from an inhibitor of the formation or action of nitric oxide in mammalian systems specifically an inhibitor of nitric oxide synthase, and hydrates, pharmaceutically acceptable salts and prodrugs thereof. There are also provided compositions containing such compounds.